Yoko Asakura

Yoko Asakura

Auto-generated profile, based on publicly available information

Yoko Asakura

Stem Cell Institute, University of Minnesota Medical School

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2018 in eLife
Verified
Journal Article
Open access
DMDespoina Mademtzoglou
Despoina Mademtzoglou
YAYoko Asakura
Yoko Asakura
MBMatthew J Borok
Matthew J Borok
Sonia Alonso-MartinSonia Alonso-Martin
Sonia Alonso-Martin
PMPhilippos Mourikis
Philippos Mourikis
Frederic RelaixFrederic Relaix
Frederic Relaix
Adult skeletal muscle maintenance and regeneration depend on efficient muscle stem cell (MuSC) functions. The mechanisms coordinating cell cycle with activation, renewal, and differentiation of MuSCs remain poorly understood. Here, we investigated how adult MuSCs are regulated by CDKN1c (p57kip2), a cyclin-dependent kinase inhibitor, using mouse molecular genetics. In the absence of CDKN1c , skeletal muscle repair is severely impaired after injury. We show that CDKN1c is not expressed in quiescent MuSCs, while being induced in activated and proliferating myoblasts and maintained in differentiating myogenic cells. In agreement, isolated Cdkn1c-deficient primary myoblasts display differentiation defects and increased proliferation. We further show that the subcellular localization of CDKN1c is dynamic; while CDKN1c is initially localized to the cytoplasm of activated/proliferating myoblasts, progressive nuclear translocation leads to growth arrest during differentiation. We propose that CDKN1c activity is restricted to differentiating myoblasts by regulated cyto-nuclear relocalization, coordinating the balance between proliferation and growth arrest.

28 February 2022 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SFShin Fujimaki
Shin Fujimaki
TMTomohiro Matsumoto
Tomohiro Matsumoto
MMMasashi Muramatsu
Masashi Muramatsu
HNHiroshi Nagahisa
Hiroshi Nagahisa
NHNaoki Horii
Naoki Horii
YOYusuke Ono
Yusuke Ono

19 May 2021 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
NKNobuko Katoku-Kikyo
Nobuko Katoku-Kikyo
EPEllen Paatela
Ellen Paatela
DHDaniel L. Houtz
Daniel L. Houtz
BLBritney Lee
Britney Lee
DMDane Munson
Dane Munson
NKNobuaki Kikyo
Nobuaki Kikyo
Circadian rhythms regulate cell proliferation and differentiation, but circadian control of tissue regeneration remains elusive at the molecular level. Here, we show that proper myoblast differentiation and muscle regeneration are regulated by the circadian master regulators Per1 and Per2. Depletion of Per1 or Per2 suppressed myoblast differentiation in vitro and muscle regeneration in vivo, demonstrating their nonredundant functions. Both Per1 and Per2 were required for the activation of Igf2, an autocrine promoter of myoblast differentiation, accompanied by Per-dependent recruitment of RNA polymerase II, dynamic histone modifications at the Igf2 promoter and enhancer, and the promoter–enhancer interaction. This circadian epigenetic priming created a preferred time window for initiating myoblast differentiation. Consistently, muscle regeneration was faster if initiated at night, when Per1, Per2, and Igf2 were highly expressed compared with morning. This study reveals the circadian timing as a significant factor for effective muscle cell differentiation and regeneration.

6 June 2024 in eLife
Verified
Journal Article
Open access
MVMayank Verma
Mayank Verma
YAYoko Asakura
Yoko Asakura
XWXuerui Wang
Xuerui Wang
KZKasey Zhou
Kasey Zhou
MÜMahmut Ünverdi
Mahmut Ünverdi
AAAtsushi Asakura
Atsushi Asakura
Endothelial and skeletal muscle lineages arise from common embryonic progenitors. Despite their shared developmental origin, adult endothelial cells (ECs) and muscle stem cells (MuSCs; satellite cells) have been thought to possess distinct gene signatures and signaling pathways. Here, we shift this paradigm by uncovering how adult MuSC behavior is affected by the expression of a subset of EC transcripts. We used several computational analyses including single-cell RNA-seq (scRNA-seq) to show that MuSCs express low levels of canonical EC markers in mice. We demonstrate that MuSC survival is regulated by one such prototypic endothelial signaling pathway (VEGFA-FLT1). Using pharmacological and genetic gain- and loss-of-function studies, we identify the FLT1-AKT1 axis as the key effector underlying VEGFA-mediated regulation of MuSC survival. All together, our data support that the VEGFA-FLT1-AKT1 pathway promotes MuSC survival during muscle regeneration, and highlights how the minor expression of select transcripts is sufficient for affecting cell behavior.

26 December 2019 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MVMayank Verma
Mayank Verma
YSYuko Shimizu-Motohashi
Yuko Shimizu-Motohashi
YAYoko Asakura
Yoko Asakura
JEJames P Ennen
James P Ennen
JBJennifer Bosco
Jennifer Bosco
AAAtsushi Asakura
Atsushi Asakura
Duchenne muscular dystrophy (DMD) is an X-linked recessive genetic disease in which the dystrophin coding for a membrane stabilizing protein is mutated. Recently, the vasculature has also shown to be perturbed in DMD and DMD model mdx mice. Recent DMD transcriptomics revealed the defects were correlated to a vascular endothelial growth factor (VEGF) signaling pathway. To reveal the relationship between DMD and VEGF signaling, mdx mice were crossed with constitutive (CAGCreERTM:Flt1LoxP/LoxP) and endothelial cell-specific conditional gene knockout mice (Cdh5CreERT2:Flt1LoxP/LoxP) for Flt1 (VEGFR1) which is a decoy receptor for VEGF. Here, we showed that while constitutive deletion of Flt1 is detrimental to the skeletal muscle function, endothelial cell-specific Flt1 deletion resulted in increased vascular density, increased satellite cell number and improvement in the DMD-associated phenotype in the mdx mice. These decreases in pathology, including improved muscle histology and function, were recapitulated in mdx mice given anti-FLT1 peptides or monoclonal antibodies, which blocked VEGF-FLT1 binding. The histological and functional improvement of dystrophic muscle by FLT1 blockade provides a novel pharmacological strategy for the potential treatment of DMD. Duchenne muscular dystrophy (DMD) is a devastating muscle disease affecting one in 5,000 newborn males, in which the gene encoding the dystrophin protein is mutated. It is a progressive muscle degenerative disease with death by either respiratory insufficiency or cardiac failure in their 20s. Recently, the vasculature has also shown to be perturbed in DMD and DMD model mdx mice with the defects correlated to a vascular endothelial growth factor (VEGF) signaling pathway. To reveal the relationship between DMD and VEGF signaling, mdx mice were crossed with mice carrying mutated a decoy receptor gene (Flt1) for VEGF. Here, we showed that Flt1 deletion resulted in increased vascular density and improvement in the DMD-associated skeletal muscle phenotype in the mdx mice. These decreases in pathology, including improved muscle histology and function, were recapitulated in mdx mice given anti-FLT1 peptides or monoclonal antibodies, which blocked VEGF-FLT1 binding. The histological and functional improvement of dystrophic muscle by FLT1 blockade provides a novel pharmacological strategy for the potential treatment of DMD.

16 March 2022 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
SFShin Fujimaki
Shin Fujimaki
TMTomohiro Matsumoto
Tomohiro Matsumoto
MMMasashi Muramatsu
Masashi Muramatsu
HNHiroshi Nagahisa
Hiroshi Nagahisa
NHNaoki Horii
Naoki Horii
YOYusuke Ono
Yusuke Ono